Cary Street Partners Investment Advisory’s Novo Nordisk NVO Stock Holding History
Bought
Maintained
Sold
Other funds holding NVO
F
EHC
Cary Street Partners Investment Advisory's NVO Position: Q2 2026 in Review
Cary Street Partners Investment Advisory increased its Novo Nordisk (NVO) stake by 114% in Q2 2026, buying an estimated $62.5K and bringing the position to 2,731 shares worth $131K. The position accounts for 0.03% of the portfolio, ranked #455.
Cary Street Partners Investment Advisory first reported a position in NVO in Q2 2022 and has held it in 16 quarters since. The position peaked at $704K in Q2 2024. 1,113 funds tracked by Wall St. Rank hold NVO as of Q2 2026.
- Cary Street Partners Investment Advisory held 2,731 shares of Novo Nordisk worth $131K as of Q2 2026.
- Cary Street Partners Investment Advisory bought 1,454 Novo Nordisk shares in Q2 2026, an estimated $62.5K.
- Novo Nordisk made up 0.03% of Cary Street Partners Investment Advisory's portfolio in Q2 2026, its #455 holding.
- Cary Street Partners Investment Advisory first reported a position in Novo Nordisk in Q2 2022 and has held it in 16 quarters since.
- Cary Street Partners Investment Advisory's Novo Nordisk position peaked at $704K in Q2 2024.
- 1,113 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.
Based on Cary Street Partners Investment Advisory's 13F filing for Q2 2026, filed 17 Jul 2026.